BioDtech, Inc. Issued New United States Patent
News Feb 20, 2013
The patent, entitled “Enhancing Endotoxin Detection,” covers the company’s EndoPrepTM and ESPTM technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.
This is the second patent issued to BioDtech for the protection of their intellectual property designed to detect Gram-negative bacteria in a sample, then remove and neutralize endotoxins, depending on their specific requirements.
“The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases,” stated Dr. Michael Pepe PhD, President and Chief Executive Officer of BioDtech. “The company is currently pursuing the potential use of this technology for the quality control and production of biotherapeutics as well as diagnostic monitoring of gastrointestinal diseases and Gram-negative bacterial infections,” added Pepe.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE